EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:6123 - ketanserin
| Formula | C22H22FN3O3 |
| Net Charge | 0 |
| Average Mass | 395.434 |
| Monoisotopic Mass | 395.16452 |
| SMILES | O=C(c1ccc(F)cc1)C1CCN(CCn2c(=O)nc3ccccc3c2=O)CC1 |
| InChI | InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29) |
| InChIKey | FPCCSQOGAWCVBH-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | EC 3.4.21.26 (prolyl oligopeptidase) inhibitor Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26). alpha-adrenergic antagonist An agent that binds to but does not activate α-adrenergic receptors thereby blocking the actions of endogenous or exogenous α-adrenergic agonists. α-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. serotonergic antagonist Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. |
| Applications: | alpha-adrenergic antagonist An agent that binds to but does not activate α-adrenergic receptors thereby blocking the actions of endogenous or exogenous α-adrenergic agonists. α-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. cardiovascular drug A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. serotonergic antagonist Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. antihypertensive agent Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| ketanserin (CHEBI:6123) has role antihypertensive agent (CHEBI:35674) |
| ketanserin (CHEBI:6123) has role cardiovascular drug (CHEBI:35554) |
| ketanserin (CHEBI:6123) has role EC 3.4.21.26 (prolyl oligopeptidase) inhibitor (CHEBI:76779) |
| ketanserin (CHEBI:6123) has role serotonergic antagonist (CHEBI:48279) |
| ketanserin (CHEBI:6123) has role α-adrenergic antagonist (CHEBI:37890) |
| ketanserin (CHEBI:6123) is a aromatic ketone (CHEBI:76224) |
| ketanserin (CHEBI:6123) is a organofluorine compound (CHEBI:37143) |
| ketanserin (CHEBI:6123) is a piperidines (CHEBI:26151) |
| ketanserin (CHEBI:6123) is a quinazolines (CHEBI:38530) |
| ketanserin (CHEBI:6123) is conjugate base of ketanserin(1+) (CHEBI:183638) |
| Incoming Relation(s) |
| ketanserin(1+) (CHEBI:183638) is conjugate acid of ketanserin (CHEBI:6123) |
| IUPAC Name |
|---|
| 3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}quinazoline-2,4(1H,3H)-dione |
| INNs | Source |
|---|---|
| ketanserin | ChemIDplus |
| ketanserine | ChemIDplus |
| ketanserinum | ChemIDplus |
| ketanserina | ChemIDplus |
| Synonyms | Source |
|---|---|
| Ketanserin | KEGG COMPOUND |
| 3-[2-[4-(4-fluorobenzoyl)-1-piperidyl]ethyl]-1H-quinazoline-2,4-dione | IUPHAR |
| Registry Numbers | Sources |
|---|---|
| Reaxys:4913068 | Reaxys |
| CAS:74050-98-9 | KEGG COMPOUND |
| CAS:74050-98-9 | ChemIDplus |
| Citations |
|---|